Sionna Therapeutics (NASDAQ:SION) Upgraded at Royal Bank Of Canada

13 Aug 2026, 06:32 by Sarita Garza · The Markets Daily

Royal Bank Of Canada upgraded shares of Sionna Therapeutics (NASDAQ:SION – Free Report) from an underperform rating to a sector perform rating in a research report released on Monday morning, Marketbeat reports. Royal Bank Of Canada currently has $5.00 price objective on the stock.

Other analysts also recently issued research reports about the company. Wedbush downgraded Sionna Therapeutics from an “outperform” rating to a “neutral” rating and set a $5.00 price objective on the stock. in a report on Monday. Raymond James Financial reiterated a “market perform” rating and issued a $59.00 target price on shares of Sionna Therapeutics in a report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Wednesday, August 5th. Wall Street Zen lowered shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Guggenheim boosted their price target on shares of Sionna Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Sionna Therapeutics currently has an average rating of “Hold” and an average price target of $42.22.

Get Our Latest Report on SION

Sionna Therapeutics Stock Up 22.5%

Shares of NASDAQ SION opened at $6.25 on Monday. The stock has a market capitalization of $282.56 million, a price-to-earnings ratio of -2.87 and a beta of 1.33. The stock’s fifty day simple moving average is $40.38 and its 200 day simple moving average is $39.67. Sionna Therapeutics has a 52-week low of $4.01 and a 52-week high of $54.97.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, analysts anticipate that Sionna Therapeutics will post -2.65 earnings per share for the current year.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 115,844 shares of Sionna Therapeutics stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the transaction, the director owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. The trade was a 4.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of Sionna Therapeutics stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the transaction, the director directly owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. This trade represents a 4.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 403,726 shares of company stock worth $18,259,354 over the last three months. 5.10% of the stock is owned by insiders.

Institutional Trading of Sionna Therapeutics

Institutional investors have recently made changes to their positions in the stock. Deutsche Bank AG increased its stake in Sionna Therapeutics by 4.5% in the 4th quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock valued at $413,000 after buying an additional 433 shares during the period. Bank of America Corp DE lifted its position in Sionna Therapeutics by 8.8% in the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after buying an additional 529 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of Sionna Therapeutics by 6.6% during the 4th quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock valued at $352,000 after buying an additional 532 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Sionna Therapeutics by 35.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after buying an additional 619 shares during the period. Finally, State of Wyoming purchased a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $35,000.

Trending Headlines about Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

Positive Sentiment: The stock’s rebound may reflect bargain hunting and short-term volatility following the steep selloff, although no new positive clinical data were reported.
Neutral Sentiment: Analyst opinion has broadly converged around a more cautious stance. Royal Bank of Canada upgraded SION to “Sector Perform,” while Stifel Nicolaus assigned a “Hold” rating. Royal Bank of Canada upgrade
Negative Sentiment: Sionna reported that its Phase 2a PreciSION CF trial of lead candidate SION-719 failed to achieve its key endpoint for sweat-chloride reduction. The drug will not advance as an add-on therapy, severely damaging the company’s near-term cystic-fibrosis development prospects. Sionna halts lead cystic fibrosis drug
Negative Sentiment: The clinical failure erased roughly 90% of SION’s market value and removed a potential competitive threat to Vertex Pharmaceuticals, whose shares benefited from the news. Vertex rises as Sionna trial fails
Negative Sentiment: Several firms reduced their ratings, including Lifesci Capital and JonesTrading to “Hold,” Wedbush to “Neutral,” Raymond James to “Market Perform,” and BTIG and Guggenheim to lower ratings. These actions signal reduced confidence after the trial result. Wedbush downgrade
Negative Sentiment: Levi & Korsinsky announced a pending investor investigation into potential securities-law violations related to disclosures that allegedly indicated SION-719 was on track before the failed trial outcome. The investigation adds legal and reputational risk. Sionna investor investigation notice

About Sionna Therapeutics

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.